DoJ Maintains Amarin 'Misplaced' Its Omega-3 Unfair Trade Argument
This article was originally published in The Rose Sheet
Executive Summary
In an amicus opposing Amarin's petition in federal court for an order that the US ITC investigate its fair trade complaint targeting certain omega-3 oil ingredients, DoJ says the drug firm is attempting private enforcement of the FDC Act. The act "commits enforcement exclusively to the federal government to ensure that complex enforcement decisions are made with the benefit of FDA's scientific and regulatory expertise," DoJ argues.
You may also be interested in...
Court Tosses Amarin Fair Trade Complaint Against Omega-3 Imports
Majority opinion by Federal Circuit upheld International Trade Commission's decision and denied as moot Amarin's petition for order to compel a judicial or government officer or agency to perform a duty. Dissenting opinion not only agrees ITC acted correctly denying the firm's complaint, but also says the commission's decision wasn't appealable. Ropes & Gray attorneys suggest ruling provides guidance for additional fair trade complaints about FDA-regulated products.
Court Tosses Amarin Fair Trade Complaint Against Omega-3 Imports
Majority opinion by Federal Circuit upheld International Trade Commission's decision and denied as moot Amarin's petition for order to compel a judicial or government officer or agency to perform a duty. Dissenting opinion not only agrees ITC acted correctly denying the firm's complaint, but also says the commission's decision wasn't appealable. Ropes & Gray attorneys suggest ruling provides guidance for additional fair trade complaints about FDA-regulated products.
FDA Clearing CBD As Dietary Ingredient? Legislation More Likely Than Rulemaking
Senate Appropriations subcommittee members add to Capitol Hill's push for FDA to change its current regulatory stance that CBD is deemed noncompliant for use in supplements and food. Commissioner Gottlieb suggests legislation authorizing FDA to allow use of CBD up to certain concentrations in supplements and food products. FDA currently allows sales of food and supplements containing CBD under enforcement discretion.